Valuation: Amgen Inc.

Market Cap 252B 1,356B 226B 208B 188B 352B 23,919B 358B 2,474B 997B 12,547B 946B 925B 39,718B P/E 2026 *
29.6x
P/E 2027 * 26.3x
Enterprise Value 293B 1,578B 263B 242B 219B 410B 27,846B 417B 2,880B 1,161B 14,607B 1,101B 1,077B 46,238B EV / Sales 2026 *
7.53x
EV / Sales 2027 * 7.11x
Free-Float
99.77%
Yield 2026 *
2.16%
Yield 2027 * 2.29%
1 day+12.97%
1 week+15.70%
1 month+16.54%
3 months+30.45%
6 months+48.49%
Current year+38.22%
1 week 77.22
Extreme 77.22
91.74
1 month 71.09
Extreme 71.09
91.74
Current year 48.4
Extreme 48.4
91.74
1 year 48.4
Extreme 48.4
91.74
3 years 45.12
Extreme 45.12
91.74
5 years 37.52
Extreme 37.52
91.74
10 years 15.78
Extreme 15.780356
91.74
Manager TitleAgeSince
Chief Executive Officer 63 2012-04-30
Director of Finance/CFO 62 2010-05-12
Chief Tech/Sci/R&D Officer 57 2023-05-31
Director TitleAgeSince
Chairman 63 2012-12-31
Director/Board Member 65 2011-12-31
Director/Board Member 71 2011-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+12.97%+15.70% - - 252B
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +3.17%+5.90%+46.58%+84.56% 473.55B
Weighted average by Cap. +2.62%+6.60%+50.51%+100.44%

Financials

2026 *2027 *
Net sales 38.97B 210B 34.93B 32.14B 29.11B 54.44B 3,700B 55.45B 383B 154B 1,941B 146B 143B 6,144B 40.4B 217B 36.21B 33.32B 30.18B 56.43B 3,835B 57.47B 397B 160B 2,012B 152B 148B 6,369B
Net income 8.56B 46.06B 7.67B 7.06B 6.39B 11.96B 813B 12.18B 84.04B 33.88B 426B 32.12B 31.43B 1,349B 9.44B 50.8B 8.46B 7.78B 7.05B 13.18B 896B 13.43B 92.68B 37.36B 470B 35.42B 34.67B 1,488B
Net Debt 41.36B 223B 37.06B 34.11B 30.89B 57.77B 3,926B 58.84B 406B 164B 2,060B 155B 152B 6,520B 35.3B 190B 31.64B 29.11B 26.37B 49.31B 3,352B 50.23B 347B 140B 1,758B 132B 130B 5,566B
Projected Income Statement - Annual - Amgen Inc.
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
26-10-30 R$91.17 +2.95% 252
26-10-29 R$88.56 +2.68% 379
26-10-28 R$86.25 +1.20% 1,316
26-10-27 R$85.23 -0.71% 65
26-10-26 R$85.84 +8.93% 415
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Amgen Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
466.01USD
Average target price
397.32USD
Spread / Average Target
-14.74%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amgen Inc.